Antineutrophil Cytoplasmic Antibody Correlates with Chronic Pouchitis after Ileal Pouch‐Anal Anastomosis

The American Journal of Gastroenterology

Volumn 90, Issue 5, 1995, Pages 740-747

  Sandborn, William J ^a,b   Landers, Carol J ^a,b   Tremaine, William J ^a,b   Targan, Stephan R ^a,b  

^a MAYO CLINIC   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE ANTIBODY;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CHRONIC DISEASE; COLON RESECTION; FEMALE; FREQUENCY ANALYSIS; GENETIC MARKER; HUMAN; ILEOSTOMY; ILEUM POUCH; IMMUNOFLUORESCENCE; INTESTINE INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECTUM ANASTOMOSIS; ULCERATIVE COLITIS;

ADENOMATOUS POLYPOSIS COLI; ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOANTIBODIES; CHRONIC DISEASE; COLITIS, ULCERATIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; INFLAMMATION; MALE; MIDDLE AGE; PROCTOCOLECTOMY, RESTORATIVE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029024487     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1995.tb09310.x     Document Type: Article

References (58)

1. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease
2. Anti‐neutrophil cytoplasmic antibodies in ulcerative colitis Comparison with other colidites/diarrhea illnesses
3. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease
4. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical and surgical treatment
5. Anti‐lactoferin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholan‐gitis, and Crohn's disease
6. Anti‐neutrophil antibodies in inflammatory bowel disease: Prevalence and diagnostic role
7. Granulocyte specific antinuclear antibodies in ulcerative colitis
8. Anti‐neutrophil nuclear antibody in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis
9. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis
10. A new type pf perinuclear anti‐neutrophil cytoplasmic antibody (pANCA) in active ulcerative colitis but not in Crohn's disease
11. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepato‐biliary diseases. High prevalence in ulcerative colitis, primary sclerosing cholangitis autoimmune hepatitis
12. Autoantibody prevalence and association in inflammatory bowel disease
13. Neutrophil auloantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity
14. Neutrophil autoantibodies. A genetic marker in primary sclerosing cholangitis and ulcerative colitis
15. Anti‐neutrophil cytoplasmic autoantibodies in relatives of patients with ulcerative colitis
16. Ulcerative colitis: A genetically heterogenous disorder defined by genetic (HLA class II) and subclin‐ical (antineutrophil cytoplasmic antibody) markers
17. Exploring the mode of inheritance of ANCA+ and ANCA‐ ulcerative colitis at the HLA locus
18. HLA DRw52a, Dw2 are not associated with the development of antineutrophil antibody type 1 (ANCA1) in ulcerative colitis (UC)
19. A subgroup of ulcerative colitis (UC) defined with genetic (HLA‐DR) and immunological (pANCA) markers
20. HLA DR2 is a susceptibility marker for UC in British patients irrespective of ANCA positivity
21. Autoantibodies in Japanese patients with ulcerative colitis are not related to genetic marker (HLA class II)
22. Molecularly defined HLA‐DR2 alleles in ulcerative colitis and an antineutrophil cytoplasmic antibody‐positive subgroup
23. The presence of antineutrophil cytoplasmic antibody correlates with pouchitis after ileal pouch‐anal anastomosis for ulcerative colitis
24. Antineutrophil cytoplasmic auto‐antibodies in sera from patients after proctocolectomy for ulcerative colitis
25. P‐ANCA development of pouchitis in ulcerative colitis patients after proctocolectomy and ileo‐anal pouch anastomosis
26. Influence of total colectomy on serum antineutrophil cytoplasmic antibodies in inflammatory bowel disease
27. Unexpectedly high prevalence of antineutrophil cytoplasmic antibody (ANCA) in patients with treatment‐resistant left‐sided ulcerative colitis (UC)
28. Anti‐neutrophil cytoplasmic antibodies (p‐ANCA) are more prevalent in ulcerative colitis patients with clinically aggressive disease
29. Ileal pouch‐anal anastomosis for chronic ulcerative colitis. Long‐term results
30. Restorative proctocolectomy with ileal reservoir
31. The clinical and functional outcome of after restorative proctocolectomy: A prospective study in 100 patients
32. Ileal pouch‐anal anastomosis. A single surgeon's experience with 100 consecutive cases
33. Pouchitis following ileal pouch‐anal anastomosis: Definition, pathogenesis, and treatment
34. Pouchitis
35. Inflammation in ileal reservoirs: “Pouchitis.”
36. Workshop: Pouchitis
37. Pouchitis after ileal pouch anal anastomosis for chronic ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis
38. Ileal pouchanal anastomosis. Patterns of failure
39. Restorative proctocolectomy with ileal reservoir: Indications and results
40. Superior results of ileoanal pullthrough (IAPT) in polyposis coli vs ulcerative colitis patients
41. Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch
42. Ileal pouch‐anal anastomosis: Comparison of results in familial adenomatous polyposis and chronic ulcerative colitis
43. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch‐anal anastomosis
44. Pouch ileitis: Recurrence of the inflammatory bowel disease in the ileal reservoir
45. Pouchitis following ileal pouch‐anal anastomosis: A pouchitis disease activity index
46. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir
47. Separation of leukocytes from blood and bone marrow
48. The utility of detection of autoantibodies against neutrophil cytoplasmic components in Wegener's granuloma‐tosis
49. The value of pANCA as a serological marker for ulcerative colitis in different European regions
50. Distinct associations of HLA class II genes with inflammatory bowel disease
51. Antibodies to Cathepsin G in Crohn's disease
52. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis
53. Is p‐ANCA in ulcerative colitis directed against beta‐glucuronidase
54. Determination of antineutrophil cytoplasmic auto‐antibodies (ANCA) specificity in sera from patients with inflammatory bowel disease
55. Neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis
56. Nuclear localization of DC specific perinuclear antineutrophil cytoplasmic antibody (pANCA) reactive antigen
57. Neutrophil cytoplasmic antibodies: A link between primary sclerosing cholangitis and ulcerative colitis
58. Complications and risk factors after ileal pouch‐anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis